GtoPdb Ligand ID: 9012

Synonyms: Example 1 [WO2011139951 A1] [3] | JNJ42165279
Compound class: Synthetic organic
Comment: JNJ-42165279 is an investigational, covalent and selective inhibitor of fatty acid amide hydrolase (FAAH) [3]. Preclinical test findings are reported in [2], with the conclusion that the favourable ADME and pharmacodynamic profiles of JNJ-42165279 supported it being progressed to clinical trial.
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 66.93
Molecular weight 410.1
XLogP 1.98
No. Lipinski's rules broken 0
Canonical SMILES O=C(N1CCN(CC1)Cc1ccc2c(c1)OC(O2)(F)F)Nc1cnccc1Cl
Isomeric SMILES O=C(N1CCN(CC1)Cc1ccc2c(c1)OC(O2)(F)F)Nc1cnccc1Cl
InChI InChI=1S/C18H17ClF2N4O3/c19-13-3-4-22-10-14(13)23-17(26)25-7-5-24(6-8-25)11-12-1-2-15-16(9-12)28-18(20,21)27-15/h1-4,9-10H,5-8,11H2,(H,23,26)
No information available.
Summary of Clinical Use
Two Phase II clinical trials evaluating JNJ-42165279 in patients with depressive disorder and anxiety (NCT02498392), or phobic disorders (NCT02432703) were suspended as a precaution, following the BIA 10-2474 Phase I trial disaster in France in January 2016 (link to Janssen's statement regarding trial suspensions).
Mechanism Of Action and Pharmacodynamic Effects
FAAH is a serine hydrolase enzyme of the endocannabinoid system which is responsible for the catabolic inactivation of the neuromodulator anandamide. FAAH inhibitors cause a build up of anandamide, which acts through activation of cannabinoid receptors to promote analgesia, and may have anti-inflammatory action [5] and prove beneficial in managing psychiatric disorders [1,4].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02432703 A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder Phase 2 Interventional Janssen Research & Development, LLC
NCT02498392 An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress Phase 2 Interventional Janssen Research & Development, LLC